|Bid price||693.50||Open price||690.50|
|Ask price||695.50||Prev close||693.50|
Register now for FREE live Dechra Pharmaceuticals share prices, Dechra Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Dechra Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Dechra Pharmaceuticals (DPH) and other London Stock Exchange equities.
Register now for FREE Dechra Pharmaceuticals share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB0009633180|
|Activites||Dechra Pharmaceuticals plc is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.||Index||FTSE 250|
|Latest Share Price (p)||693.50||Net Gearing (%)||50.04|
|Market Capitalisation (£m)||606.09||Gross Gearing (%)||57.94|
|Shares in issue (m)||87.71||Debt Ratio||43.96|
|P/E Ratio||33.56||Debt-to-Equity Ratio||0.57|
|Total dividends per share (p)||14.00||Assets / Equity Ratio||2.38|
|Dividend Yield (%)||2.09||Price to book value||3.47|
|Dividend cover (x)||1.25||ROCE||0.05|
|Earning per share (p)||20.59||EPS Growth (%)||31.57|
|52 week high / low||755.00 / 655.00||DPS Growth (%)||14.10|
|Dec.Date||Type||Director||Pos||No. of Shares|
/* */ RNS Number : 3872N Dechra Pharmaceuticals PLC 25 July 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to...
Dechra Pharmaceuticals said group revenue for the year to end-June was up by approximately 1.6% at constant currency compared to the prior year. · Positive momentum with improved revenue growth for H2 at 3.7%, compared to a decline of 0.7% in H1 (all at constant currency); · All EU...
Dechra Pharmaceuticals' group revenue for the year to the end of June rose by approximately 1.6% at constant currency from last year - around 2.3% at actual exchange rates. The group saw positive momentum with improved revenue growth for H2 at 3.7%, compared to a decline of 0.7% in H1 (all at...
Register now for FREE Dechra Pharmaceuticals company news
A really dreary share! Dechra Pharmaceuticals manufactures and distributes vetinary products and equiptment.Has a few own brands:- Equipalazone,Vetoryl and Felimazole -anyone used them? My stockbroker molested me so much over this company that I finally bought at 130p,(Feb 04); now at 182.5p...
Register now for FREE Dechra Pharmaceuticals share price discussions